Lundbeck

Neurvati Neurosciences Announces Appointment of Deborah Dunsire, MD, as Member and Chair of Company Board of Directors

Retrieved on: 
星期一, 四月 15, 2024
Takeda Pharmaceutical Company, University, Woman of the Year, Lundbeck, Takeda Oncology, Retirement, Growth, Woman, Pharmaceutical industry

NEW YORK, April 15, 2024 /PRNewswire/ -- Neurvati Neurosciences, a clinical-stage biotechnology company dedicated to bringing a new generation of proven-effective therapies to people affected by neurological and psychiatric disorders, today announced the appointment of Dr. Deborah Dunsire as a new member and the new chair of the company's board of directors.

Key Points: 
  • NEW YORK, April 15, 2024 /PRNewswire/ -- Neurvati Neurosciences, a clinical-stage biotechnology company dedicated to bringing a new generation of proven-effective therapies to people affected by neurological and psychiatric disorders, today announced the appointment of Dr. Deborah Dunsire as a new member and the new chair of the company's board of directors.
  • "We are very excited to welcome Dr. Dunsire to the Neurvati board of directors.
  • She previously served as president, CEO and a director of XTuit Pharmaceuticals, Inc., a private biopharmaceutical company, and president, CEO and a director of FORUM Pharmaceuticals.
  • "I am delighted to be joining the Neurvati Neurosciences board of directors at such an exciting time for the company with many pivotal business development and clinical milestones pending," said Dr. Dunsire.

Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI® (eptinezumab-jjmr) at 76th Annual Meeting of the American Academy of Neurology

Retrieved on: 
星期二, 四月 9, 2024
Health, Other Science, General Health, Clinical Trials, Research, Science, Pharmaceutical, Hypersensitivity, Anaphylaxis, Angioedema, Brain, Eptinezumab, Virtual Private LAN Service, Headache, Patient, American Academy, Interview, MD, Neurology, Migraine, Lundbeck, Quality of life, AAN, Abstract, Pharmaceutical industry

These data will be presented during an oral session at the 76th Annual Meeting of the American Academy of Neurology (AAN) taking place in Denver, Colo., and virtually from April 13-18, 2024.

Key Points: 
  • These data will be presented during an oral session at the 76th Annual Meeting of the American Academy of Neurology (AAN) taking place in Denver, Colo., and virtually from April 13-18, 2024.
  • “Our real-world data helps us better understand how individuals are uniquely impacted by migraine beyond monthly headache days.
  • We’re excited to continually partner with the migraine community to raise the bar on preventive treatment expectations.”
    VYEPTI is indicated for the preventive treatment of migraine in adults.
  • The safety and efficacy of VYEPTI has not been evaluated for use in any psychiatric conditions.

Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease

Retrieved on: 
星期一, 三月 18, 2024
Research, FDA, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Week, Psychosis, Agitation, Commercialization, Medication, Psychiatry, Caregiver, Patient, Geriatric psychiatry, Overalls, MD, Lundbeck, NPI, CMAI, Neuropsychiatry, Safety, Poster, Behavioral neuroscience, Multimedia, Dementia, Annual general meeting, Food

One poster utilized the Neuropsychiatric Inventory (NPI) to explore the relationship of REXULTI on neuropsychiatric symptoms relating to agitation and occupational disruptiveness/caregiver distress related to patients’ behavior.

Key Points: 
  • One poster utilized the Neuropsychiatric Inventory (NPI) to explore the relationship of REXULTI on neuropsychiatric symptoms relating to agitation and occupational disruptiveness/caregiver distress related to patients’ behavior.
  • The NPI, which is administered through a structured caregiver interview, is comprised of 12 domains of neuropsychiatric symptoms including agitation/aggression, irritability/lability, and disinhibition.
  • The analysis demonstrated that REXULTI was associated with reductions in overall neuropsychiatric symptoms and in agitation symptoms (as captured by the NPI) compared with placebo over 12 weeks.
  • “The breadth of data presented at AAGP represents our continued commitment to understanding the full potential of REXULTI on agitation associated with dementia due to Alzheimer’s disease.”

Non-Postoperative Acute Pain Treatment Market to Exhibit Enormous Growth During the Study Period (2019-2032) | DelveInsight

Retrieved on: 
星期五, 一月 26, 2024
Patient, Surgery, Infection, Research, Trauma, LAS, Analgesic, Injury, Diagnosis, Pain, Pain management, Rehabilitation, Ice, Nonsteroidal anti-inflammatory drug, Meditation, Anesthetic, USD, Physical examination, Burns, RICE, Lundbeck, QOL, Vertex Pharmaceuticals, Growth, Pharmaceutical industry

LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.

Key Points: 
  • LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.
  • Leading non-postoperative acute pain companies such as Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others are developing novel non-postoperative acute pain drugs that can be available in the non-postoperative acute pain market in the coming years.
  • The non-postoperative acute pain epidemiology section provides insights into the historical and current non-postoperative acute pain patient pool and forecasted trends for the US.
  • To know more about non-postoperative acute pain treatment guidelines, visit @ Non-Postoperative Acute Pain Management
    The dynamics of the non-postoperative acute pain market are expected to change in the coming years.

Non-Postoperative Acute Pain Treatment Market to Exhibit Enormous Growth During the Study Period (2019-2032) | DelveInsight

Retrieved on: 
星期五, 一月 26, 2024
Patient, Surgery, Infection, Research, Trauma, LAS, Analgesic, Injury, Diagnosis, Pain, Pain management, Rehabilitation, Ice, Nonsteroidal anti-inflammatory drug, Meditation, Anesthetic, USD, Physical examination, Burns, RICE, Lundbeck, QOL, Vertex Pharmaceuticals, Growth, Pharmaceutical industry

LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.

Key Points: 
  • LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.
  • Leading non-postoperative acute pain companies such as Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others are developing novel non-postoperative acute pain drugs that can be available in the non-postoperative acute pain market in the coming years.
  • The non-postoperative acute pain epidemiology section provides insights into the historical and current non-postoperative acute pain patient pool and forecasted trends for the US.
  • To know more about non-postoperative acute pain treatment guidelines, visit @ Non-Postoperative Acute Pain Management
    The dynamics of the non-postoperative acute pain market are expected to change in the coming years.

Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors

Retrieved on: 
星期三, 一月 10, 2024
University, Amgen, Therapy, Senior management, ADC, Religious studies, MBA, Acquisition, Harvard Business School, BLA, Lundbeck, Management

LONDON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Robert W. Azelby to the Board of Directors.

Key Points: 
  • LONDON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Robert W. Azelby to the Board of Directors.
  • Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to Autolus’s Board.
  • “The Autolus Board and Management Team would like to welcome Bob Azelby to the Board of Directors.
  • He currently serves on the Board of Directors at ADC Therapeutics SA and has also served on the Board of Directors of Chinook Therapeutics Inc, Clovis Oncology Inc., Eliem Therapeutics Inc., Alder BioPharmaceuticals Inc., Cascadian Therapeutics, Inc., and Immunomedics, Inc.

 Virpax Pharmaceuticals Announces Leadership Transition

Retrieved on: 
星期五, 十一月 17, 2023
Biotechnology, Health, Finance, Other Health, Pharmaceutical, Surgery, Professional Services, Other Science, Practice Management, Medical Devices, Infectious Diseases, Hospitals, Science, Veterinary, CNS, Neurogenic inflammation, Silence Therapeutics, Meharry Medical College, Pharmaceutical marketing, Regulatory affairs, Therapy, Post-traumatic stress disorder, Quality assurance, Lincoln University, Commercial Operating System, Pain management, Patient, INSEAD, Merck, Medication, Clobazam, Nitrome, Sanofi, Trustee, Novartis, University, Harvard Medical School, Axovant Sciences, Tennessee State University, Champaign–Urbana metropolitan area, Central nervous system, Business, DSM-IV codes, International business, Pharmaceutical industry, Management, Analgesic, Schizophrenia, Biology, Neurophysiology, Lundbeck, Neuroscience, Droxidopa

Prior to Virpax, Mr. Bruce served as Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.

Key Points: 
  • Prior to Virpax, Mr. Bruce served as Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.
  • He has a BA from Lincoln University and a Master’s degree in Leadership from Georgetown University’s McDonough School of Business.
  • Aside from Virpax Pharmaceuticals, he also serves on the board of Advent Therapeutics Inc. and is a member of the Board of Trustees of Meharry Medical College.
  • I am proud of what we have accomplished together and confident that Virpax under Gerald and Eric’s leadership will remain on track to begin first-in-human trials in the coming year,” commented Mr. Mack.

HARMONY BIOSCIENCES APPOINTS PETER ANASTASIOU TO ITS BOARD OF DIRECTORS

Retrieved on: 
星期三, 十一月 8, 2023
Therapy, Economics, Neuronetics, Eli Lilly, Eli Lilly and Company, CNS, MBA, HBA, R, BA, Growth, Albion College, Harmony, Bristol Myers Squibb, DSM-IV codes, Neurology, Healthcare Businesswomen's Association, Business, Parity, Indiana University, Patient, Pharmaceutical industry, Management, Lundbeck

PLYMOUTH MEETING, Pa., Nov. 8, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Peter Anastasiou to the Company's Board of Directors.

Key Points: 
  • PLYMOUTH MEETING, Pa., Nov. 8, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Peter Anastasiou to the Company's Board of Directors.
  • Anastasiou held various leadership positions at Lundbeck, where he was critical in shaping overall corporate strategy, R&D priorities, and business development.
  • "I am energized to join Harmony's Board of Directors at this critical stage of growth for the company.
  • "Peter's CNS and business development expertise will support Harmony's growth priorities," said Harmony Biosciences Chairman Jeff Aronin.

Kynexis Launched to Advance Precision Therapeutics for Brain Diseases

Retrieved on: 
星期二, 十一月 7, 2023
Molecule, Psychosis, Biomarker, Therapy, Rare, Biotechnology, Genetics, Psychiatry, Novo Nordisk, CNS, Deficit spending, Access, Mitsubishi Tanabe Pharma, Metabolism, Clinic, Lundbeck, Myenteric plexus, Lead candidate, Medicine, Drug discovery, Neurology, Maryland School, Cognitive deficit, University, Health, Brain, Roche, Kynurenine, Cognition, Pharmaceutical industry, Management, CIAS, Schizophrenia, Takeda, Pfizer, Series

NAARDEN, The Netherlands, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, launched today with €57 million in Series A financing led by Forbion, with participation from Ysios Capital and Sunstone Life Science Ventures. Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.

Key Points: 
  • Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.
  • Dr. Schwarcz pioneered the study of the kynurenine pathway in the brain, which established kynurenine’s substantive role in cognition and in the pathophysiology of schizophrenia.
  • Through the convergence of human genetics, biomarkers, and deep phenotyping, Kynexis is well-positioned to pursue a novel, precision psychiatry-based approach to develop KYN-5356 in CIAS.
  • Under the terms of the agreement, Kynexis has an exclusive worldwide license from MTPC to develop and commercialize KYN-5356 worldwide.

JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease

Retrieved on: 
星期一, 十一月 6, 2023
Research, Mental Health, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Behavioral neuroscience, Attention, Headache, Incidence, CMAI, Food, Mini–Mental State Examination, DSM-IV codes, Brexpiprazole, OPDC, MD, Psychiatry, Food and Drug Administration Amendments Act of 2007, Deficit spending, Verbal aggression, Dementia, Multimedia, Medicine, Interview, Pneumonia, Somnolence, Lundbeck, Locomotion, Commercialization, JAMA Neurology, Cachexia, Screaming, Caregiver, Passive-aggressive behavior, Aggression, Saint Louis University School of Medicine, MMSE, Heart, Ōtsuka, Akathisia, Contra body movement, Agitation, Medication, Tearing, Anxiety, IPA, Patient, Diagnosis, Disease, Restless, Pharmaceutical industry, Nursing, Birth control

REXULTI is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease.

Key Points: 
  • REXULTI is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease.
  • Participants also required a diagnosis that met The International Psychogeriatric Association’s (IPA) provisional definition of agitation in patients with cognitive impairment or dementia.
  • “Agitation associated with dementia due to Alzheimer’s disease can be very challenging and emotionally distressing for patients and family members caring for them.
  • The trial had high rates of patients completing the trial: 86.8% of the brexpiprazole group and 88.9% of the placebo group.